ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2025
Neural networks to estimate multiple sclerosis disability and predict progression using routinely collected healthcare data.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ozanimod Reduces Serum Neurofilament Light Chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) and Modulates Innate and Adaptive Immunity in Patients with Low-to-Moderate Activity Relapsing-Remitting Multiple Sclerosis.International journal of molecular sciences · 2026Observational
- Patient-reported outcomes as predictors of disability evolution in Multiple Sclerosis: An interpretable machine learning approach.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- A Comparative Study of Clinical and Demographic Profiles of Multiple Sclerosis Patients in Two Regional Centers in Denmark and Romania.Neurology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMultiple sclerosis (MS)-related disability is conventionally measured using the Expanded Disability Status Scale (EDSS), which requires neurological examination and is generally embedded in clinical records, making it unavailable in administrative datasets. This limits its utility for population-level estimates and healthcare planning. This study aims to use routinely collected healthcare data to fill this gap.
methodsWe conducted a population-based study using administrative data from Campania Region (Italy) to develop and validate neural network algorithms to estimate MS-related disability and predict its progression (2015-2021). We employed a deep learning approach to estimate the EDSS, and a hybrid model combining survival analysis with neural network predictions to forecast the risk of EDSS progression.
resultsThe model estimated EDSS with 0.68 accuracy, 0.68 precision, and 0.67 F1-score. The hybrid model had a predictive performance of 0.92. From 2016 to 2021, 9.01% of the population had EDSS ⩽ 3.0, 62.10% had EDSS between 3.5 and 5.5, and 28.89% had EDSS ⩾ 6.0. Looking at projections from 2021 to 2026, 67.68% people with EDSS ⩽ 3.0 are expected to progress to EDSS 3.5-5.5.
conclusionThese findings highlight the potential of advanced data analytics using administrative data to improve MS monitoring, healthcare planning, and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.